in Stem Cell Therapeutics
Number of registered patents in Korea and overseas
Number of national R&D grants received in Korea
Number of private cord blood units stored
Percentage of R&D staff
1st Generation Cord Blood-derived Stem Cell Products
PNEUMOSTEM® an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is currently under development for the preventive treatment of Bronchopulmonary Dysplasia(BPD) in premature infants. Currently, Phase 2 clinical trial is ongoing in Korea and PNEUMOSTEM® has been Orphan Drug designated by US FDA and EMA. Recently, US FDA granted a Fast Track Designation for PNEUMOSTEM®.
2nd Generation Cord Blood-derived Stem Cell Products